Navigation Links
MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
Date:12/21/2010

MOUNTAIN VIEW, Calif., Dec. 21, 2010 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced completion of the LEVADEX open-label safety trial.  The Company has now completed the final trial necessary to support a New Drug Application (NDA) for LEVADEX and plans to submit an NDA in the first half of 2011.  LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 clinical development for the acute treatment of migraine.

"We are pleased to have completed the LEVADEX clinical program. This clinical trial completes a comprehensive 505(b)(2) clinical development program which evaluated the efficacy, safety, pharmacokinetics and pharmacodynamics of LEVADEX in approximately 1,000 patients," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "In 2010, we announced that a second Phase 3 trial would not be necessary for our NDA submission, completed and announced successful results from a pharmacokinetics trial in smokers, a pharmacodynamics trial evaluating pulmonary artery pressure and a thorough QT trial, and we have now completed our open-label safety trial."  

The 12 month open-label, safety extension of the Phase 3 FREEDOM-301 trial was designed to evaluate overall safety of LEVADEX over six and 12 months of exposure.  In total, more than 475 patients completed six months treatment and more than 250 patients completed 12 months treatment.  In this trial no drug-related serious adverse events were reported.

The Company anticipates presenting safety results from the trial at an upcoming scientific conference.  

About LEVADEX™LEVADEX orally inhaled migraine therapy is a novel migraine therapy in Phase 3 development. Patients administer LEVADEX themselves using the company's proprietary TEMPO® inhaler. LEVADEX has b
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
2. Lotus Pharmaceuticals Announces Change of Directors
3. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
4. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
5. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
6. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. John A. MacPhee Resigns From Strativa Pharmaceuticals
8. Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
9. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
11. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014   BioNano Genomics announced today achievement of ... collect human data at 30X depth, sufficient for a genome ... capability was established and demonstrated for the IrysChip TM ... System and will be rolled out to BioNano,s collaborators ... showcasing this advancement at the American Society for Human ...
(Date:10/20/2014)... 2014 Pharmaceutic Labs announces the opening of ... Albany, NY for admixing, compounding, drug shortages ... exceeds the FDA standards for safety and quality, using ... The 10,000 square foot outsourcing facility ... assurance and quality control. The company will produce sterile ...
(Date:10/19/2014)... 20, 2014 Shire plc (LSE: SHP, NASDAQ: ... Chief Financial Officer (CFO), has notified the Board of Directors of ... a new career opportunity as CFO of Severn Trent plc.  James ... company will commence a search for a new CFO immediately. ... has helped build and lead a high-quality finance team at Shire. ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... ANTONIO, Oct. 6 Nautilus Neurosciences, Inc., ... Pharmacal Company, a privately-held pharmaceutical company focused ... their exclusive co-promotion agreement for CAMBIA™ (diclofenac ... and other women,s health medical professionals. CAMBIA™ ...
... Gerresheimer Reports Strong Earnings and Sales Growth -- DUSSELDORF, Germany, October 6, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 2Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 3Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 4Gerresheimer Reports Strong Earnings and Sales Growth 2Gerresheimer Reports Strong Earnings and Sales Growth 3Gerresheimer Reports Strong Earnings and Sales Growth 4Gerresheimer Reports Strong Earnings and Sales Growth 5Gerresheimer Reports Strong Earnings and Sales Growth 6Gerresheimer Reports Strong Earnings and Sales Growth 7Gerresheimer Reports Strong Earnings and Sales Growth 8Gerresheimer Reports Strong Earnings and Sales Growth 9
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Unveiled at the ... Strategic Direction Scorecard conservatively estimates member hospital ROI on membership ... on dues, The Center provides $12.50 in value to member ... (Member Value – Member Dues)/Member Dues. , “This is ... this number and we think the methodology is really sound,” ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... his innovative True Form Tummy Tuck® method ... faculty at The University of Texas Medical Branch ... a medical student. Patronella, who is a founding partner ... practices in Texas, The Aesthetic Center for Plastic ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... running, jogging on physical health have been known for a ... Germany that running can improve the mental health status as ... // ,The study participants had to complete a minimum of ... had to take up progressively difficult tests. The researchers examined ...
... has been lifted on account of no single case of bird ... racing, falconry and other bird shows were regularly conducted in Britain.// ... which was detected in Eastern Europe the events were banned to ... of bird flu was reported the health officials are planning to ...
... of two drugs in a rare medical trail. These drugs ... ,They are anti-retroviral drugs which have been studied individually ... are unapproved for the usage in AIDS patient and hence ... usage of this new unapproved AIDS drug started nine months ...
... human cancer cells in a unique way will be ... Zealand. The clinical trial would be held at New ... on Wednesday. ,Auckland University cancer researcher Professor Bill ... is converted to a DNA damaging agent in the ...
... treatment of Ambylopia or lazy eye as it is commonly called. ... at the USC and three other Chinese universities. //,A ... compromise in the vision even when corrective glasses are used. If ... condition has been regarded to be incurable in children over 8 ...
... says that elderly white women who have had non-melanoma skin ... of their exposure to the harmful rays of the sun. ... age group of 50 to 79, who had a previous ... the skin, had a two-fold increase in the risk of ...
Cached Medicine News:Health News:Health Canada Gave Access To Unapproved Drugs To AIDS/HIV Patients. 2
... Our new oversized wheelchair scales incorporate all ... model including automatic zero, weight recall, reweigh ... displays weight in pounds and kilos., ... patients in electric and oversized wheelchairs. The ...
This high-capacity stand-on scale provides extra sensitivity and support to patients who are unsteady on their feet. Advanced technology compensates for patient movement....
... Endo-PAT2000 is a simple and easy to ... PAT signal is recorded using Itamar Medical's ... is analyzed automatically using proprietary advanced Digital ... within seconds of completing the test. The ...
... C-peptide of insulin is the C-terminal cleavage ... prohormone to the mature insulin molecule. Although ... it does undergo significant liver or extra-renal ... circulating half-life than insulin [1]. In addition, ...
Medicine Products: